Critical Reviews in Oncology/Hematology

IFC
pp. CO2-CO2(1)

Targeted Therapies and the Treatment of Genitourinary Cancers, The First Annual Opinion Leader Summit
pp. 1-2(2)
Author: Vogelzang N.J.

Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer
pp. 3-10(8)
Authors: van Leenders G.J.L.H.; Schalken J.A.

Searching for the gatekeeper oncogene of prostate cancer
pp. 11-20(10)
Author: Gelmann E.P.

Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center
pp. 21-31(11)
Authors: Morris M.J.; Scher H.I.

Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma
pp. 33-39(7)
Author: Motzer R.J.

Angiogenesis inhibitors in genitourinary cancers
pp. 41-47(7)
Authors: Stadler W.; Wilding G.

Current status of thalidomide and its role in the treatment of metastatic prostate cancer
pp. 49-57(9)
Authors: Macpherson G.R.; Franks M.; Tomoaia-Cotisel A.; Ando Y.; Price D.K.; Figg W.D.

Thalidomide therapy for renal cell carcinoma
pp. 59-65(7)
Author: Amato R.J.

Therapeutic approaches to bladder cancer: identifying targets and mechanisms
pp. 67-83(17)
Authors: Cote R.J.; Datar R.H.

Novel approaches with targeted therapies in bladder cancer - Therapy of bladder cancer by blockade of the epidermal growth factor receptor family
pp. 85-104(20)
Authors: Bellmunt J.; Hussain M.; Dinney C.P.

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers
pp. 105-115(11)
Authors: Sternberg C.N.; Vogelzang N.J.

The potential for prostate cancer immunotherapy
pp. 117-125(9)
Authors: Rini B.I.; Small E.J.